Fintel reports that on December 10, 2024, D. Boral Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...
Fintel reports that on December 11, 2024, Chardan Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported ...
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...
Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal ...
Morgan Stanley double downgraded CervoMed (CRVO) to Underweight from Overweight without a price target saying multiple questions remain for ...
Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...